A Phase 3 interventional study of 18F-FDG PET/CT in Pericarditis, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Ottawa Heart Institute Research Corporation · Phase 3, Interventional, and Diagnostic
The pericardium is a thin, double-layered sac around the heart that helps reduce friction as the heart moves. When this sac gets inflamed, it is called pericarditis, which can cause serious health problems and even be life-threatening. Pericarditis often comes back after the first episode. About 10-30% of people will have it again, and half of those will have it multiple times. Although there are treatments available, they are costly and not often used because we can't predict who best to use them on. Finding a way to predict which patients would benefit from these treatments could help reduce the burden on patients and the healthcare system.
This study will use a test called an 18F-FDG PET/CT with CTA Scan (18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) with computer tomography angiography (CTA)) to measure inflammation in the pericardium.
The purpose of the study is to create easy-to-use tools for doctors to identify people at high risk of pericarditis coming back, so they can get advanced treatment early. This study will help fill knowledge gaps about key predictors like clinical signs, blood tests, and imaging results.
This is a single-center, prospective cohort study designed to compare imaging biomarkers identified by CMR and FDG PET between patients who experience recurrent pericarditis and those who do not. In this prospective study, 44 patients will be recruited from the Ottawa Pericardial Clinic, all with a history of recurrent pericarditis. These patients will be followed prospectively for a period of one year.
It is hypothesized that patients who develop further episodes of recurrent pericarditis will exhibit significantly elevated markers of pericardial inflammation on both FDG PET/CT imaging as well as CMR imaging.
54 studies on the registry are indexed under Pericarditis; 23 are open to participants now.
This study's planned enrollment of 44 is below the median of 60 across 29 interventional studies indexed under Pericarditis.
Browse Pericarditis studies →Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Given
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a single arm study. Participants enrolled will complete blood and imaging tests.
Diagnostic Test: 18F-FDG PET/CT
The participants will under an 18F-FDG PET/CT with CTA.
Pericardial contrast uptake on late gadolinium enhancement (LGE) on CMR
Pericardial imaging by CMR to evaluate inflammation
Time frame: At Baseline
Circumferential linear increased FDG signal uptake
Pericardial Imaging to indicate pericardial inflammation.
Time frame: baseline
Recurrent pericarditis
\# of participants that experience pericarditis recurrence after the qualifying occurrence
Time frame: From baseline to 1 year
Clinical Factor - Age
Participant Age
Time frame: At Baseline
Clinical Factor - Sex
Sex of participant
Time frame: At Baseline
Clinical Factor - Family history of auto-immune disease
Presence of family history of auto-immune disease
Time frame: baseline
Clinical Factor - Heart Rate
Resting Heart rate of \>80beats per minute
Time frame: At Baseline
Serum biomarkers - C-Reactive Protein
C-Reactive protein levels
Time frame: At Baseline
Serum biomarkers - Erythrocyte sedimentation rate (ESR)
ESR level
Time frame: At Baseline
Serum biomarkers - carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1)
CEACAM1 levels
Time frame: At Baseline
Serum biomarkers - MHC class I chain related protein A (MICA)
MICA levels
Time frame: At Baseline
Serum biomarkers - MHC Class I chain related protein B (MICB)
MICB levels
Time frame: At Baseline
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Heart Institute Research Corporation →